Franklin Resources
IOVA icon

Franklin Resources’s Iovance Biotherapeutics IOVA Stock Holding History

Franklin Resources’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.6K Buy
+11,283
New +$36.1K ﹤0.01% 3029
2025
Q2 		– Sell
-87,129
Closed -$290K – 3078
2025
Q1 		$290K Sell
87,129
-13,100
-13% -$67.6K ﹤0.01% 2504
2024
Q4 		$742K Hold
100,229
– – ﹤0.01% 2123
2024
Q3 		$979K Buy
100,229
+8,470
+9% +$80.2K ﹤0.01% 1994
2024
Q2 		$736K Buy
91,759
+51,658
+129% +$554K ﹤0.01% 2067
2024
Q1 		$594K Buy
40,101
+4,333
+12% +$50.4K ﹤0.01% 2169
2023
Q4 		$291K Buy
35,768
+10,751
+43% +$56.3K ﹤0.01% 2187
2023
Q3 		$114K Buy
25,017
+6,674
+36% +$43.6K ﹤0.01% 2438
2023
Q2 		$129K Sell
18,343
-2,681,640
-99% -$19.2M ﹤0.01% 2488
2023
Q1 		$16.5M Sell
2,699,983
-599,239
-18% -$4.13M 0.01% 821
2022
Q4 		$21.1M Sell
3,299,222
-1,882,924
-36% -$14.7M 0.01% 755
2022
Q3 		$49.6M Buy
5,182,146
+14,639
+0.3% +$169K 0.03% 524
2022
Q2 		$57M Sell
5,167,507
-219,071
-4% -$2.87M 0.03% 512
2022
Q1 		$89.7M Sell
5,386,578
-411,138
-7% -$6.36M 0.04% 458
2021
Q4 		$111M Sell
5,797,716
-471,707
-8% -$10.4M 0.04% 440
2021
Q3 		$155M Sell
6,269,423
-957,650
-13% -$22.6M 0.06% 358
2021
Q2 		$188M Sell
7,227,073
-1,783,897
-20% -$46.4M 0.07% 301
2021
Q1 		$285M Buy
9,010,970
+82,066
+0.9% +$3.4M 0.12% 213
2020
Q4 		$414M Buy
8,928,904
+610,359
+7% +$24.2M 0.18% 152
2020
Q3 		$274M Buy
8,318,545
+1,358,111
+20% +$41.6M 0.13% 194
2020
Q2 		$203M Buy
6,960,434
+1,729,557
+33% +$56.9M 0.1% 234
2020
Q1 		$157M Sell
5,230,877
-246,879
-5% -$6.54M 0.1% 222
2019
Q4 		$152M Sell
5,477,756
-1,089,720
-17% -$24.8M 0.08% 282
2019
Q3 		$120M Sell
6,567,476
-487,506
-7% -$10.8M 0.06% 319
2019
Q2 		$173M Sell
7,054,982
-1,229,917
-15% -$18.5M 0.09% 257
2019
Q1 		$78.8M Buy
8,284,899
+1,435
+0% +$13.9K 0.04% 429
2018
Q4 		$73.3M Buy
8,283,464
+3,099,311
+60% +$29.9M 0.04% 405
2018
Q3 		$58.3M Sell
5,184,153
-124,782
-2% -$1.77M 0.03% 497
2018
Q2 		$68M Sell
5,308,935
-1,228
-0% -$17.9K 0.03% 456
2018
Q1 		$89.7M Buy
5,310,163
+330,697
+7% +$5.01M 0.05% 390
2017
Q4 		$39.8M Sell
4,979,466
-225,825
-4% -$1.81M 0.02% 589
2017
Q3 		$40.3M Buy
5,205,291
+56,461
+1% +$357K 0.02% 591
2017
Q2 		$37.8M Sell
5,148,830
-71,216
-1% -$453K 0.02% 608
2017
Q1 		$38.9M Buy
5,220,046
+6,718
+0.1% +$49.2K 0.02% 600
2016
Q4 		$36.2M Buy
5,213,328
+3,032,228
+139% +$20.9M 0.02% 620
2016
Q3 		$17.9M Sell
2,181,100
-1,207,400
-36% -$10.2M 0.01% 833
2016
Q2 		$26.5M Buy
3,388,500
+1,210,500
+56% +$7.6M 0.01% 724
2016
Q1 		$11.1M Hold
2,178,000
– – 0.01% 959
2015
Q4 		$16.8M Buy
2,178,000
+71,900
+3% +$499K 0.01% 892
2015
Q3 		$12.1M Hold
2,106,100
– – 0.01% 971
2015
Q2 		$19.3M Buy
2,106,100
+786,100
+60% +$8.77M 0.01% 896
2015
Q1 		$16M Buy
+1,320,000
New +$14.9M 0.01% 940

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Franklin Resources's IOVA Position: Q1 2026 in Review

Franklin Resources opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2026: 11,283 shares worth $39.6K. The stake represents ﹤0.01% of the portfolio and ranks #3029 among its holdings. This is a return to the name: Franklin Resources previously reported a position in IOVA as recently as Q1 2025.

Franklin Resources first reported a position in IOVA in Q1 2015 and has held it in 42 quarters since. The position peaked at $414M in Q4 2020. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Franklin Resources held 11,283 shares of Iovance Biotherapeutics worth $39.6K as of Q1 2026.
  • Iovance Biotherapeutics was a new Franklin Resources position in Q1 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q1 2026, its #3029 holding.
  • Franklin Resources first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 42 quarters since.
  • Franklin Resources's Iovance Biotherapeutics position peaked at $414M in Q4 2020.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Franklin Resources's 13F filing for Q1 2026, filed 13 May 2026.